CN104619857A - 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法 - Google Patents

用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法 Download PDF

Info

Publication number
CN104619857A
CN104619857A CN201280074120.5A CN201280074120A CN104619857A CN 104619857 A CN104619857 A CN 104619857A CN 201280074120 A CN201280074120 A CN 201280074120A CN 104619857 A CN104619857 A CN 104619857A
Authority
CN
China
Prior art keywords
defibrotide
euglobulin
plasmin
biological activity
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280074120.5A
Other languages
English (en)
Chinese (zh)
Inventor
T·伊诺尼
V·库马尔
K·伊斯拉姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gentium SRL
Original Assignee
Gentium SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46829846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104619857(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gentium SRL filed Critical Gentium SRL
Priority to CN201910228570.9A priority Critical patent/CN110079580B/zh
Publication of CN104619857A publication Critical patent/CN104619857A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/968—Plasmin, i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CN201280074120.5A 2012-06-22 2012-06-22 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法 Pending CN104619857A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910228570.9A CN110079580B (zh) 2012-06-22 2012-06-22 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2012/000193 WO2013190582A1 (en) 2012-06-22 2012-06-22 Euglobulin-based method for determining the biological activity of defibrotide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910228570.9A Division CN110079580B (zh) 2012-06-22 2012-06-22 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法

Publications (1)

Publication Number Publication Date
CN104619857A true CN104619857A (zh) 2015-05-13

Family

ID=46829846

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280074120.5A Pending CN104619857A (zh) 2012-06-22 2012-06-22 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法
CN201910228570.9A Active CN110079580B (zh) 2012-06-22 2012-06-22 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910228570.9A Active CN110079580B (zh) 2012-06-22 2012-06-22 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法

Country Status (16)

Country Link
US (9) US9902952B2 (cg-RX-API-DMAC7.html)
EP (1) EP2864496B2 (cg-RX-API-DMAC7.html)
JP (1) JP6198821B2 (cg-RX-API-DMAC7.html)
KR (4) KR102038357B1 (cg-RX-API-DMAC7.html)
CN (2) CN104619857A (cg-RX-API-DMAC7.html)
AU (1) AU2012383169B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014031934B1 (cg-RX-API-DMAC7.html)
CA (1) CA2874960C (cg-RX-API-DMAC7.html)
DK (1) DK2864496T4 (cg-RX-API-DMAC7.html)
ES (1) ES2660969T5 (cg-RX-API-DMAC7.html)
IL (1) IL236132B (cg-RX-API-DMAC7.html)
IN (1) IN2014DN10584A (cg-RX-API-DMAC7.html)
MX (1) MX352085B (cg-RX-API-DMAC7.html)
RU (1) RU2627177C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201408481UA (cg-RX-API-DMAC7.html)
WO (1) WO2013190582A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107109458A (zh) * 2014-11-27 2017-08-29 真蒂奥姆责任有限公司 基于细胞的去纤维蛋白多核苷酸效力测定方法
CN111132663A (zh) * 2017-08-03 2020-05-08 爵士制药爱尔兰有限公司 包含高浓度核酸的制剂

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
KR102038357B1 (ko) 2012-06-22 2019-10-31 젠티엄 에스알엘 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
JP7150733B2 (ja) * 2017-01-25 2022-10-11 ケメット エレクトロニクス コーポレーション 自己減衰型mlccアレイ
AU2019252790A1 (en) 2018-04-12 2020-10-15 Jazz Pharmaceuticals, Inc. Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
WO2021174039A1 (en) 2020-02-28 2021-09-02 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
TW202308659A (zh) 2021-05-06 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN87103688A (zh) * 1986-04-17 1988-01-20 克利诺斯农场生物工业联合股票公司 聚脱氧核苷酸的制备工艺
CN1612938A (zh) * 2001-12-17 2005-05-04 金蒂姆股份公司 去纤肽生物学活性的测定方法
CN101688235A (zh) * 2007-06-07 2010-03-31 国家健康医学研究所 用于测量存在于生物学流体样品中的微颗粒的纤溶酶活性的方法及用途

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899481A (en) 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
DE2154279A1 (de) 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
IT1043823B (it) 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
DE2812943C3 (de) 1978-03-23 1981-05-14 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Reagens zur Bestimmung der biologischen Aktivität von Heparin im Plasma
US4853221A (en) 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
IT1170214B (it) 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1170215B (it) 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta
IT1206341B (it) 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
US5231006A (en) 1986-10-16 1993-07-27 Behringwerke Aktiengesellschaft Method for the determination of plasminogen
US4753221A (en) 1986-10-22 1988-06-28 Intravascular Surgical Instruments, Inc. Blood pumping catheter and method of use
JP2907447B2 (ja) 1988-08-24 1999-06-21 中外製薬株式会社 抗血栓剤
IT1231509B (it) 1989-09-07 1991-12-07 Crinos Industria Farmaco Composizione farmceutica ad uso topico per la terapia della fragilita' capillare.
JPH0539280A (ja) * 1990-07-20 1993-02-19 Takeda Chem Ind Ltd サツカロアスコルビン酸誘導体および血栓症予防治療剤
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US6699985B2 (en) 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
US5624912A (en) 1991-08-21 1997-04-29 Burcoglu; Arsinur Method of treating HIV infection and related secondary infections with defibrotide
US5977083A (en) 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
IT1252174B (it) 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
JPH08127539A (ja) 1994-10-31 1996-05-21 Ajinomoto Co Inc ヒトil−11を含有する末梢血幹細胞増加剤
US5856444A (en) 1994-11-30 1999-01-05 Chugai Seiyaku Kabushiki Kaisha Thrombocytopoiesis stimulating factor
ATE299030T1 (de) 1996-07-10 2005-07-15 Meiji Dairies Corp Verwendung von proteinen aus der mk familie als hämatopoietischer faktor
AU754242B2 (en) 1997-04-28 2002-11-07 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
WO1998054313A2 (en) 1997-05-30 1998-12-03 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6177545B1 (en) 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
DE19740384A1 (de) 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
GB9719161D0 (en) 1997-09-09 1997-11-12 Glaxo Group Ltd New therapeutic method
US6573372B2 (en) 1999-01-07 2003-06-03 Heska Corporation Feline immunoglobulin E molecules and compositions there of
CA2377385A1 (en) 1999-06-03 2000-12-14 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
ES2251134T3 (es) 1999-06-08 2006-04-16 Gentium S.P.A. Uso de complejos entre liposomas cationicos y polidesoxirribonucleotidos como medicamentos.
US8771663B2 (en) 2000-04-18 2014-07-08 Gentium Spa Formulation having mobilising activity
EP1147777A1 (en) 2000-04-18 2001-10-24 Crinos Industria Farmacobiologica S.p.A. Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
CA2426540A1 (en) 2000-10-20 2002-07-25 Biocardia, Inc. Leukocyte expression profiling
EP1356071B1 (en) 2000-11-28 2007-11-21 The University of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
PL366223A1 (en) 2000-12-29 2005-01-24 Bio-Technology General Corp. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6770753B2 (en) 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
AU2002353783A1 (en) 2001-09-24 2003-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
CN1304011C (zh) 2002-05-31 2007-03-14 雷根斯堡大学医学院 保护性寡聚脱氧核糖核苷酸的制药用途
US20050215498A1 (en) 2002-05-31 2005-09-29 Guenther Eissner Method for the protection of endothelial and epithclial cells during chemotherapy
AU2003263764A1 (en) 2002-07-01 2004-01-19 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
US20060293256A1 (en) 2002-08-06 2006-12-28 Masateru Yamada Remedy or preventive for kidney disease and method of diagnosing kidney disease
US20050196382A1 (en) 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
WO2005089503A2 (en) 2004-03-19 2005-09-29 Progenics Pharmaceuticals, Inc. Cd4-igg2 formulations
AU2005289774B2 (en) * 2004-09-22 2012-03-08 The Regents Of The University Of Colorado Methods for a global assay of coagulation and fibrinolysis
US7723127B2 (en) 2005-03-03 2010-05-25 Novx Systems Inc. Immunoassay with extended dynamic range
KR20070121001A (ko) 2005-03-03 2007-12-26 젠티엄 에스피에이 신혈관 형성-의존성 종양 치료용 약학적 제제
WO2006119619A1 (en) 2005-05-06 2006-11-16 Replicor Inc. Oligonucleotides inhibiting cell proliferation
EP1872787A1 (en) 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP1982722A1 (en) 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
EP2183598A1 (en) 2007-07-13 2010-05-12 Elan Pharmaceuticals Inc. Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase
EP2103689A1 (en) 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
JP2011522515A (ja) 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用
CN101301306A (zh) 2008-06-30 2008-11-12 广东天普生化医药股份有限公司 Dft在制备治疗和预防休克药物中的应用
JP5789521B2 (ja) 2009-03-03 2015-10-07 グリフオルス・セラピユーテイクス・インコーポレーテツドGrifols Therapeutics,Inc. プラスミノーゲンを製造するための組成物、方法およびキット;ならびにそれから製造されるプラスミン
CN107233337A (zh) * 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
WO2011057143A1 (en) * 2009-11-06 2011-05-12 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for simultaneous assay of thrombin and plasmin generation
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
KR102038357B1 (ko) 2012-06-22 2019-10-31 젠티엄 에스알엘 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
CN111132663A (zh) 2017-08-03 2020-05-08 爵士制药爱尔兰有限公司 包含高浓度核酸的制剂
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
WO2021174039A1 (en) 2020-02-28 2021-09-02 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN87103688A (zh) * 1986-04-17 1988-01-20 克利诺斯农场生物工业联合股票公司 聚脱氧核苷酸的制备工艺
CN1612938A (zh) * 2001-12-17 2005-05-04 金蒂姆股份公司 去纤肽生物学活性的测定方法
CN101688235A (zh) * 2007-06-07 2010-03-31 国家健康医学研究所 用于测量存在于生物学流体样品中的微颗粒的纤溶酶活性的方法及用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PAUL G. RICHARDSON ET AL: "Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial", 《NATIONAL INSTITUTES OF HEALTH》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107109458A (zh) * 2014-11-27 2017-08-29 真蒂奥姆责任有限公司 基于细胞的去纤维蛋白多核苷酸效力测定方法
CN107109458B (zh) * 2014-11-27 2021-10-26 真蒂奥姆责任有限公司 基于细胞的去纤维蛋白多核苷酸效力测定方法
CN111132663A (zh) * 2017-08-03 2020-05-08 爵士制药爱尔兰有限公司 包含高浓度核酸的制剂

Also Published As

Publication number Publication date
US20150176003A1 (en) 2015-06-25
KR20190112197A (ko) 2019-10-02
ES2660969T3 (es) 2018-03-26
JP6198821B2 (ja) 2017-09-20
IN2014DN10584A (cg-RX-API-DMAC7.html) 2015-08-28
RU2627177C2 (ru) 2017-08-03
US20210363519A1 (en) 2021-11-25
US11085043B2 (en) 2021-08-10
DK2864496T4 (da) 2021-01-04
US11236328B2 (en) 2022-02-01
CA2874960A1 (en) 2013-12-27
US9902952B2 (en) 2018-02-27
US20180334672A1 (en) 2018-11-22
BR112014031934B1 (pt) 2021-05-04
CN110079580A (zh) 2019-08-02
US20210388350A1 (en) 2021-12-16
BR112014031934A2 (pt) 2017-06-27
CN110079580B (zh) 2022-12-06
ES2660969T5 (es) 2021-09-03
US12529052B2 (en) 2026-01-20
US20250236866A1 (en) 2025-07-24
DK2864496T3 (en) 2018-01-15
US20200208148A1 (en) 2020-07-02
US20250075206A1 (en) 2025-03-06
EP2864496B2 (en) 2020-11-25
KR20190016148A (ko) 2019-02-15
KR101948243B1 (ko) 2019-05-21
AU2012383169B2 (en) 2017-12-21
US20250236867A1 (en) 2025-07-24
IL236132A0 (en) 2015-01-29
CA2874960C (en) 2021-05-18
BR112014031934A8 (pt) 2018-01-02
KR20180098420A (ko) 2018-09-03
US11746348B2 (en) 2023-09-05
JP2015521477A (ja) 2015-07-30
IL236132B (en) 2018-07-31
MX352085B (es) 2017-11-08
SG11201408481UA (en) 2015-01-29
EP2864496B1 (en) 2017-11-29
EP2864496A1 (en) 2015-04-29
US12534722B2 (en) 2026-01-27
AU2012383169A1 (en) 2015-01-15
KR20150044877A (ko) 2015-04-27
MX2014016114A (es) 2015-09-23
KR102038357B1 (ko) 2019-10-31
WO2013190582A1 (en) 2013-12-27
US20230357762A1 (en) 2023-11-09
RU2014149089A (ru) 2016-08-10
HK1208503A1 (en) 2016-03-04

Similar Documents

Publication Publication Date Title
US12534722B2 (en) Euglobulin-based method for determining the biological activity of defibrotide
CN100408690C (zh) 去纤肽生物学活性的测定方法
RU2766143C2 (ru) Жидкая композиция дефибротида для лечения и профилактики веноокклюзионной болезни
TWI615473B (zh) 用於測定去纖維蛋白多核苷酸的生物活性之基於優球蛋白的方法
CA1324748C (en) Assays for t-plasminogen activator and plasminogen activator inhibitor
HK1208503B (en) Euglobulin-based method for determining the biological activity of defibrotide
SA113350049B1 (ar) طريقة تعتمد على جلوبولين حقيقي لتحديد النشاط الحيوي لديفيبروتيد

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Italy gualdi town

Applicant after: It Diaomu Limited Liability Company

Address before: Italy gualdi town

Applicant before: Gentium S.P.A.

COR Change of bibliographic data
RJ01 Rejection of invention patent application after publication

Application publication date: 20150513

RJ01 Rejection of invention patent application after publication